Home » Thought Leadership » Blogs

Blogs

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 15 posts
Regulators and HTA Bodies
August 24, 2021 | Blogs, Infographics

Drug Assessment Uncertainties: HTA Bodies vs. Regulators

A recent study of the review of new medicines by regulatory and HTA bodies has revealed areas of misalignment in their processes, highlighting unique challenges in the pathway to patient access.

Novel Combinations Double the Trouble
May 25, 2021 | Blogs

Novel Combinations: Double the Trouble

Launching a novel combination therapy provides a unique set of challenges and opportunities when seeking to achieve positive pricing and access outcomes. In this article, CBPartners reviewed the pricing and access outcomes from prior novel immuno-oncology combinations and have developed considerations for manufacturers developing strategies for their future pipeline.

eu in pills
April 14, 2020 | Blogs

The COVID-19 Pandemic: Pricing and Access Outlook for Future Innovative Drugs in Europe

Disruption in healthcare systems across Europe is rife due to the COVID-19 pandemic, with increasingly strained budgets, and shifting healthcare priorities.

Tumour case study
March 24, 2020 | Blogs

Tumor-Agnostic Therapies: The Complex Path to Commercial Viability

The tumor-agnostic space is incredibly exciting and an area that is likely to be explored further. CBPartners’ blog post addresses the current precision medicine landscape, touching upon challenges, as well as key commercial considerations.

Gene editing case study
March 24, 2020 | Blogs

Genome Editing: An Introduction

A topic that is becoming increasingly popular in the healthcare space is Genome Editing. CBPartners’ Cell and Gene Therapy Center of Excellence team explores the development of these technologies as they present an immense opportunity for the future of the pharmaceutical industry.